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a b s t r a c t
Endoplasmic reticulum (ER) stress is involved in the pathophysiology of atherosclerosis. Insults interfering
with ER function lead to the accumulation of unfolded and misfolded proteins in the ER that initiates the
unfolded protein response (UPR). When the UPR fails to control the level of unfolded and misfolded
proteins, ER-initiated apoptotic signaling is induced. We evaluated: (1) the UPR and ER-initiated apoptotic
signaling in peripheral blood mononuclear cells (PBMCs) of stable coronary artery disease (CAD) patients;
(2) PBMC content of oxidation products of phospholipid 1-palmitoyl-2-arachidonyl-sn-glycero-3-phos-
phorylcholine (oxPAPC); (3) the possible origin of oxPAPC in PBMCs; and (4) the expression of nuclear
erythroid-related factor 2 (Nrf2)/antioxidant-related element (ARE), a cellular defense mechanism.
Twenty-nine CAD patients and 28 matched controls were enrolled. Expression of glucose-regulated
protein 78 kDa (GRP78/BiP), as a representative of the UPR, and of C/EBP homologous protein (CHOP), as a
representative of ER apoptosis, was signiﬁcantly higher in CAD than in controls (po0.01). Concentrations
of oxPAPC in PBMCs, in plasma, and in low-density lipoprotein (LDL) were signiﬁcantly higher in CAD
compared to controls (po0.01). The oxPAPC in PBMCs may derive from circulating ox-LDL. Nrf2/ARE gene
expression and circulating and cellular glutathione were signiﬁcantly lower in CAD compared to controls
(po0.01). In in vitro studies, increasing amounts of oxPAPC induced a dose-dependent increase in CHOP
and apoptosis-related protein expression (po0.01) and a progressive decrease in Nrf2/ARE gene
expression (po0.01). In PBMCs of CAD patients there is an activation of the UPR and ER-initiated apoptotic
signaling, possibly related to an abnormal concentration of oxPAPC in PBMCs.
& 2013 Elsevier Inc. All rights reserved.
Coronary artery disease is a common complex atherosclerotic
pathology associated with substantial morbidity and mortality [1,2].
Work over the past decade has revealed that endoplasmic
reticulum (ER)1 stress is an important event during the initiation,
progression, and clinical progression of atherosclerosis [3]. It is known
that a variety of insults can interfere with ER function, leading to the
accumulation of unfolded and misfolded proteins in the ER [4,5]. In
particular, it has been shown that oxidation products of phospholipid
1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (oxPAPC)
leads to ER stress and activation of the unfolded protein response
(UPR) in human aortic endothelial cells [6]. When ER stress occurs,
three ER transmembrane sensors are activated to initiate adaptive
responses [4,5,7]. These sensors include protein kinase-like ER kinase
(PERK), inositol-requiring kinase 1, and the transcriptional factor
activating transcription factor 6. All three sensors are maintained in
an inactive state through the interaction of their N-terminus with
glucose-regulated protein 78 kDa (GRP78) [8]. When unfolded pro-
teins accumulate in the ER, GRP78 releases these sensors to allow
their oligomerization and thereby initiates the UPR [9]. Once the UPR
fails to control the level of unfolded and misfolded proteins in the ER,
ER-initiated apoptotic signaling is induced with the activation of the
death factor, CCAAT/enhancer binding protein homologous protein
(CHOP) [4,5,7–9]. In this context, reduced apoptosis and plaque
necrosis have been shown in mice lacking CHOP [10], providing
direct evidence for a causal link between the ER-stress effector CHOP
and plaque progression.
The UPR also generates excess levels of reactive oxygen species
(ROS), a process that is driven by proteins involving new protein
disulﬁde isomerase and ER oxidoreduction [11]. One of the most
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important cellular defense mechanisms against excess ROS is
regulated by nuclear erythroid-related factor 2 (Nrf2), a PERK-
dependent master transcriptional activator, which regulates many
of the antioxidant defense genes [12,13].
Because we have previously demonstrated a progressive increase
in oxidative–inﬂammatory markers and monocyte activation from
control subjects to stable and to unstable angina patients [14–16], in
this study we evaluated: (1) the UPR and the ER-initiated apoptotic
signaling in peripheral blood mononuclear cells (PBMCs) of stable
coronary artery disease (CAD) patients; (2) the PBMC content of
oxPAPC; (3) the possible origin of oxPAPC in PBMCs; and (4) the
PBMC expression of Nrf2/antioxidant-related element (ARE).
Material and methods
Study population
The study was approved by the hospital ethics committee in
accordance with the ethical standard of the Declaration of Hel-
sinki, and informed consent was obtained from all the patients
before their enrolment.
Major requirements for the enrolment in all the groups were
absence of infectious or acute/chronic inﬂammatory diseases or
known malignancy and absence of acute/chronic renal failure,
hepatic failure, or diabetes mellitus.
Two groups of subjects were studied: 29 patients with stable
CAD and 28 control healthy (C) subjects. The CAD patients were
enrolled on the basis of previously established criteria [14–17].
For CAD patients exclusion criteria were prior coronary artery
bypass grafting, recent (o6 months) myocardial infarction (MI),
recent (o6 months) percutaneous coronary intervention (PCI) or
congestive heart failure, and coronary tree free of signiﬁcant
coronary artery disease (deﬁned as at least one stenosis with
minimal luminal diameter 470% of the arterial lumen by visual
estimate) detected at coronary angiography.
The 28 C subjects were nurses or physicians from the Depart-
ment of Internal Medicine, University of Verona Medical School,
who had no cardiovascular risk factors (hypertension, cigarette
smoking, diabetes mellitus, hypercholesterolemia, obesity, family
history of premature cardiovascular disease), no continuative drug
therapy, and no history of cardiovascular disease or valvular heart
disease. The following data were obtained from all the patients:
age, sex, presence of cardiovascular risk factors (hypertension,
cigarette smoking, diabetes mellitus, hypercholesterolemia, family
history of ischemic coronary artery disease), use of medications,
previous MI, previous PCI.
Blood samples, low-density lipoprotein (LDL), and PBMC isolation
Venous blood samples were obtained from C subjects and CAD
patients after 12 h fasting. Blood was collected from each subject
and drawn into pyrogen-free blood collection tubes. Multiple
aliquots of serum or plasma were placed into sterile 1-ml screw-
capped polypropylene vials, containing the phenolic antioxidant
2,6-di-tert-butyl-4-methylphenol (BHT; 10 mM; Sigma, Milan, Italy)
to inhibit lipid peroxidation, and stored at 80 1C. Samples were
kept frozen for no longer than 9 months, with an average of
5 months. The samples were frozen and thawed only once. PBMCs
were isolated as previously described [16]. Total cholesterol, high-
density lipoprotein (HDL) cholesterol, LDL cholesterol, triglycerides,
and glucose were measured with standard methods. C-reactive
protein (CRP) was measured using a commercially available high-
sensitivity turbidimetric method (Syncron-PCR, Beckman Coulter,
Brea, CA, USA). Plasma for LDL separation was frozen and stored as
previously reported [18]. Samples were kept frozen for no longer
than 12 months, with an average of 7 months, and thawed only
once. LDL was separated by sequential ﬂotation as described [14].
Evaluation of oxPAPC in PBMCs, plasma, and LDL from C subjects and
CAD patients
OxPAPC in PBMCs and plasma of controls and CAD patients
were measured on an Agilent mass spectrometer equipped with
an electrospray source (Agilent Technologies, Milan, Italy) as
previously described [19]. The following different oxPAPC were
taken into consideration: 1-palmitoyl-2-(5,6-epoxyisoprostane
E2)-sn-glycero-3-phosphorylcholine (PEIPC), 1-palmitoyl-2-(5-
oxovaleroyl)-sn-glycero-3-phosphorylcholine (POVPC), and 1-pal-
mitoyl-2-glutaroyl-sn-glycero-3-phosphorylcholine (PGPC). Flow-
injection experiments were performed on an HPLC system
(HP1100, Agilent Technologies). Quantiﬁcation of the peak areas
was performed by single-ion monitoring in the elution time range
of 10–20 min using appropriate software. Authentic 1-palmitoyl-
2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC), POVPC,
and PGPC were obtained from Avanti Polar Lipids, Inc. (Delfzijl,
The Netherlands). PEIPC was prepared and analyzed in our
laboratory as previously described [20].
Glutathione (GSH) measurement in plasma and in PBMCs
The detailed procedures for the measurement of cellular and
plasma GSH have been previously described [19]. Samples were
collected directly into specially prepared tubes containing the
preservative BHT (10 mM), to reduce autoxidation, and frozen at
80 1C. Samples were analyzed using high-performance liquid
chromatography with ﬂuorescence detection of 7-ﬂuorobenzo-2-
oxa-1, 3-diazol-4-sulfonic acid at excitation 385 nm and emission
515 nm.
Oxidized (ox) LDL measurement in plasma
Circulating plasma ox-LDL levels were measured with the Mer-
codia oxidized LDL enzyme-linked immunosorbent assay (Mercodia
AB) as previously described [14]. Cu2þ-modiﬁed LDL ranging from 50
to 500 ng/ml was used as a standard solution.
In vitro analysis
To verify whether ox-LDL or serum is a possible source of cellular
oxPAPC, THP-1 monocytoid cells were incubated with increasing
amounts (from 0 to 600 mg of LDL protein/ml) of native (n) and ox-
LDL and of serum (from 0 to 50% in culture medium) derived from
CAD patients and healthy C in the presence of BHT (10 mM) for 6 h,
and cellular PGPC and POVPC were measured as described. LDL and
Cu2þ-modiﬁed LDL were prepared as reported [14]. Immediately
before the incubation with THP-1 cells, LDL was separated from
diffusible low-molecular-mass compounds by gel ﬁltration on a PD-10
Sephadex G-25 M gel in 10 mM phosphate-buffered saline. As for
serum, THP-1 cells were incubated without and with increasing
amounts (10, 30, and 50% of culture medium) of serum derived from
CAD patients and healthy C for 6 h. THP-1 cells were also incubated
with the corresponding amounts (10, 30, and 50% of culture medium)
of lipoprotein-depleted serum (LPDS) derived from CAD patients,
from which all the lipoproteins were taken away by ultracentrifuga-
tion at a density 41.21 g/ml, as previously described [16].
To study the relationship between the UPR and the ER-initiated
apoptotic signaling with the Nrf2/ARE response and the cellular
content of oxPAPC, THP-1 monocytoid cells were incubated with
crescent concentrations of PGPC (in a range from 0 to 1.6 ng/mg
PAPC) with or without the presence of the inhibitor of NADPH
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oxidase diphenyliodonium (DPI; 50 mM) for 6 h, and ROS, GSH,
GRP78/BiP, CHOP and Nrf2/ARE gene expression was evaluated.
Intracellular ROS production was quantiﬁed through the oxida-
tion of 20,70-dichloroﬂuorescin diacetate as previously described
[21].
Endotoxin contamination of cell cultures involving the use of
LDL and serum was routinely excluded with the chromogenic
Limulus amoebocyte lysate assay (Sigma). Early apoptosis and cell
viability were determined using the Annexin V–FITC Kit (Bender
MedSystems, Vienna, Austria) and 7-amino-actinomycin D (BD
Biosciences, Buccinasco, Italy) by ﬂow cytometry.
Quantitative real-time PCR
Quantitative real-time PCR analysis was performed as pre-
viously described [16]. Total RNA was extracted from PBMCs with
an RNeasy Mini Kit (Qiagen, Milan, Italy) and was reverse tran-
scribed using an IScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA,
USA). The relative expression levels of mRNA encoding GRP78/BiP,
CHOP, Nrf2, heme oxygenase-1 (HO-1), glutamate–cysteine ligase
catalytic (GCLC) subunit, p53, BAX, BID, caspase 3, and caspase
9 were measured by an iCycler (Bio-Rad), using IQSYBR Green PCR
SuperMix (Bio-Rad) and 300 nM each primer pair. Primers were
designed by Beacon Design 4.0 software (Premier Biosoft Interna-
tional, Palo Alto, CA, USA) and synthesized by MWG Biotech AG
(Ebersberg, Germany) [16]. Normalized gene expression levels are
given as the ratio between the mean value for the target gene and
that for the β-actin in each sample.
Western blot analysis
Western blot analysis was performed as previously described
[16]. GRP78/BiP, CHOP, Nrf2, HO-1, GCLC subunit, p53, BAX, BID,
caspase 3, and caspase 9 were immunoprecipitated from 1 mg of
each PBMC protein lysate or nuclear lysate with mouse mono-
clonal antibodies and anti-β-actin (Santa Cruz Biotechnology,
Heidelberg, Germany). Immune complexes were captured with
protein A/G–Sepharose beads (Pierce, Rockford, IL, USA) for 2 h,
and the beads were washed four times with 100 mM NaCl.
To ensure the speciﬁcity of protein–antibody interaction, lysates
were incubated with beads in the absence of antibody as well as
with an irrelevant immunoglobulin isotype control (Caltag, Little
Balmer, UK). GRP78/BiP, CHOP, Nrf2, HO-1, GCLC subunit, and p53
were detected by probing immunoprecipitates with rabbit poly-
clonal antibodies (Santa Cruz Biotechnology), followed by goat
anti-rabbit horseradish peroxidase-conjugated secondary anti-
body (Bio-Rad). Reactive antigens were visualized with Super-
signal chemiluminescence substrate (Pierce) and quantiﬁed by
densitometric analysis with ChemiDoc XRS (Bio-Rad). Protein
expression data were quantiﬁed with Quantity One Software
(Bio-Rad).
Statistical analysis
Data are expressed as mean7standard deviation (SD) values if
normally distributed. Differences between groups were analyzed
by a two-tailed unpaired Student t test and by one-way ANOVA
and post hoc multiple comparison using Student–Newman–Keuls0
test. A probability value (p) o0.05 was considered statistically
signiﬁcant.
Results
Baseline characteristics of the patients
Baseline clinical characteristics and laboratory data of CAD
patients and healthy C are described in Table 1.
There were no statistical differences in clinical and metabolic
characteristics between the two groups.
Plasma levels of high-sensitivity (hs)-CRP and ox-LDL were
signiﬁcantly higher in CAD patients than in healthy C (po0.05),
whereas plasma and PBMC concentrations of GSH were signiﬁ-
cantly lower in CAD patients than in healthy C (po0.05).
Drug therapies were similar in the CAD group (acetylsalicylic
acid, angiotensin-converting enzyme inhibitor, β-blocker, and
statin).
UPR activation and Nrf2/ARE response in PBMCs and oxPAPC
concentrations in plasma, LDL, and PBMCs of CAD patients and
healthy C
Figs. 1a and b show the mRNA and protein expression of
GRP78/BiP, CHOP, Nrf2, HO-1, and GCLC subunit in PBMCs of all
CAD patients and healthy C considered in this study. GRP78/BiP
and CHOP were signiﬁcantly higher in CAD patients than in
healthy C (po0.01). Despite UPR activation there was no Nrf2/
ARE gene response in CAD patients and the mRNA and protein
expression of Nrf2, HO-1, and GCLC subunit was signiﬁcantly lower
than in healthy C (po0.01).
Figs. 1c and d also show the concentrations of oxPAPC in plasma,
LDL, and PBMCs of all CAD patients and healthy C considered in this
study. The plasma, LDL, and PBMC concentrations of oxPAPC mea-
sured in this study (PEIPC, POVPC, PGPC) were signiﬁcantly higher in
CAD patients than in healthy C (po0.01).
OxLDL and serum as a source oxPAPC in THP-1 cells
To verify whether ox-LDL or serum is a possible source of cellular
oxPAPC, THP-1 cells were incubated with increasing amounts of
n- and ox-LDL and of serum derived from CAD patients and healthy
C in the presence of BHT (10 mM) for 6 h, and cellular oxPAPC were
measured as described. Figs. 2a and b show that the incubation of
Table 1
Clinical characteristics and values of metabolic, inﬂammatory, and oxidative
parameters in C and CAD.C, healthy controls; CAD, stable coronary artery disease
patients; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; HsCRP, high-sensitivity C-reactive protein; GSH, glutathione; Ox-LDL,
oxidized low-density lipoprotein; NS, not signiﬁcantly different; data are expressed
as the mean7SD.
C (n¼28) CAD (n¼29) p
Age (years) 64710 66710 NS
Male/female 14/14 15/14 NS
BMI (kg/m2) 25.572 2572 NS
SBP (mm Hg) 13075 12875 NS
DBP (mm Hg) 8075 7973 NS
Heart rate (bpm) 6775 6675 NS
Total cholesterol (mg/dl) 16375 15575 NS
LDL cholesterol (mg/dl) 10075 10076 NS
HDL cholesterol (mg/dl) 5275 4975 NS
Triglycerides (mg/dl) 12476 12077 NS
Plasma glucose (mg/dl) 9878 10178 NS
HsCRP (mg/dl) 0.0670.006 0.370.03 o0.01
Plasma GSH (mmol/L) 3.9771.23 2.4970.94 o0.01
PBMC GSH (ng/mg cell protein) 2.6470.15 1.6570.75 o0.01
Ox-LDL (mg/ml) 14.2170.79 25.6071.12 o0.01
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ox-LDL but not of n-LDL with THP-1 cells determined a dose-
dependent increase in cellular content of oxPAPC (POVPC and PGPC;
po0.01).
The incubation of THP-1 cells with increasing amounts of
serum derived from CAD patients but not from healthy C for 6 h
in the presence of BHT resulted in a dose-dependent signiﬁcant
increase in oxPAPC (POVPC and PGPC) in THP-1 cells (p from
o0.05 to o0.001; Figs. 2c and d). The concentrations of POVPC
and PGPC in THP-1 cells were in a range similar to those found in
circulating PBMCs (from 0.5 to 2.5 ng of POVPC or PGPC/mg PAPC).
Because the majority of circulating oxPAPC is carried by lipopro-
teins, we used LPDS to eliminate their effect from the CAD
patients0 sera. The incubation of THP-1 cells with LPDS almost
completely abolished the increase in cellular oxPAPC (Figs. 2c and
d), indicating that the serum lipoproteins may be one of the major
sources of oxPAPC of circulating cells.
GRP78/BiP, CHOP, and Nrf2/ARE gene expression in THP-1 cells
enriched with serum and LPDS from CAD patients and healthy C
Figs. 3a and b show the mRNA and protein expression of
GRP78/BiP, CHOP, Nrf2, OH-1, and GCLC subunit in THP-1 cells
enriched with serum and LPDS of CAD patients and healthy C after
6 h of incubation. The expression of GRP78/BiP and CHOP was
higher in THP-1 cells enriched with serum derived from CAD
patients than from healthy C (po0.001). In contrast, there was no
response of Nrf2, HO-1, or GCLC mRNA and protein expression in
THP-1 cells enriched with the serum of CAD patients, whereas it
was signiﬁcantly higher in the cells derived from healthy C
(po0.001). When THP-1 cells were incubated with LPDS derived
from CAD patients, only small, and not signiﬁcant, variations in
GRP78/BiP and Nrf2/ARE gene expression were observed.
Effects of PGPC on ROS generation and GRP78/BiP, CHOP,
and Nrf2/ARE gene expression
THP-1 cells incubated with increasing amounts of PGPC (in the
range from 0 to 1.6 ng/mg PAPC) showed a dose-dependent
increase in ROS generation (po0.01; Fig. 4a). The generation of
ROS in THP-1 cells was greatly reduced in the presence of the
NADPH oxidase inhibitor DPI (po0.01). At variance with ROS, GSH
dose-dependently increased only at 0.4 and 0.8 ng PGPC/mg PAPC,
whereas at higher concentrations it signiﬁcantly decreased
(Fig. 4b; po0.01). As shown in Fig. 4b, DPI reversed almost
completely the reduction in GSH induced by the highest concen-
trations of PGPC (po0.01).
We also found that PGPC dose-dependently increased the
mRNA and protein expression of GRP78/BiP and CHOP (po0.01),
which was reduced by DPI (po0.01; Figs. 5a and b). Otherwise,
the behavior of Nrf2/ARE gene expression induced by PGPC was
different depending on its concentration. At low concentrations,
PGPC evoked a dose-dependent rise in Nrf2, HO-1, and GCLC
(po0.01), whereas at higher concentrations, it reduced Nrf2/ARE
gene expression (po0.01; Figs. 5c and d). As shown in Figs. 5c and
d, DPI reversed the reduction in Nrf2/ARE gene expression induced
by the highest concentrations of PGPC (po0.01).
Discussion
In this study we have for the ﬁrst time demonstrated that the
expression of GRP78/BiP, as a representative of UPR, and of CHOP,
as a representative of ER-initiated apoptotic signaling, was sig-
niﬁcantly higher in PBMCs of CAD patients compared to those
of healthy C. ER stress and UPR activation markers have been
Fig. 1. GRP78/BiP, CHOP, Nrf2, HO-1, and GCLC mRNA and protein expression in PBMCs and oxPAPC concentrations in circulation and in PBMCs of all stable CAD patients and
healthy controls (C). (a) mRNA of GRP78/BiP, CHOP, Nrf2, HO-1, and GCLC was analyzed by quantitative real-time PCR. Normalized gene expression levels are given as the
ratio between the mean value for the target gene and that for the β-actin in each sample. (b) Representative Western blot analysis for the indicated proteins and the average
quantiﬁcation obtained by densitometric analysis of all the samples derived from healthy C and CAD patients. Data from the Western blot analysis are expressed as the
density ratio of target protein (row 1) to control (β-actin) (row 2) in arbitrary units. (c) Serum and LDL concentrations of oxPAPC (PEIPC, POVPC, and PGPC) in healthy C and
CAD patients. (d) OxPAPC (PEIPC, POVPC, and PGPC) concentrations in PBMCs of healthy C and CAD patients. Data represent the mean7SD of measurements performed in
triplicate in all CAD patients and healthy C. npo0.001 vs healthy C.
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observed in both human and animal atherosclerotic lesions.
Myoishi et al. [22] examined histological sections of human
atherosclerotic coronary artery lesions obtained at autopsy or
after directional coronary atherectomy [22]. Both smooth muscle
cells and macrophages exhibited a markedly increased expression
of the ER chaperones GRP78 and GRP94 and CHOP in thin-cap
atheroma and ruptured plaques compared with intimal thicken-
ing, ﬁbrous plaques, and thick-cap atheroma. Actually advanced
atherosclerotic plaques have a pathophysiological environment
that causes ER stress and activates the UPR owing to the presence
of oxidized lipids, inﬂammation, and metabolic stress [23,24]. The
fact that UPR and CHOP are activated in PBMCs of CAD patients
indicates also that the circulating environment may be somehow
altered in CAD patients. In this study we have shown that
inﬂammation, altered redox state of PBMCs, and abnormal levels
of ox-LDL are chronically present in patients with CAD, over the
acute event, despite achievement of the correct targets for glucose,
lipid, and blood pressure values. CAD patients, in fact, presented
higher plasma levels of hs-CRP and ox-LDL and lower circulating
GSH than healthy C. These results are substantially in line with
previous studies [25–27] and in particular with our previous
reports [14–16] in which hs-CRP levels and ox-LDL concentrations
were higher in stable angina patients than in controls. In this
context, ox-LDL has already been shown to trigger ER stress in
vascular cells in vitro [28]. In addition, it has been established that
oxidized lipids can induce ER stress and apoptosis in human aortic
smooth muscle cells [28] and cause the death of macrophages via
a CHOP-dependent pathway, with this process being inhibited by
antioxidants [22]. In particular it has been shown that oxPAPC
leads to ER stress and activation of the UPR in human aortic
Fig. 2. OxPAPC in THP-1 incubated with native and oxidized LDL and with serum and LPDS. Increasing amounts of n-LDL and Cu2þ-modiﬁed LDL were incubated with THP-1
cells for 6 h at 37 1C and the following cellular oxPAPC were measured: (a) POVPC and (b) PGPC. Increasing amounts of serum (10, 30, and 50%) derived from stable CAD
patients and healthy controls (C) were also incubated with THP-1 cells for 6 at 37 1C and (c) POVPC and (d) PGPC were measured. Finally THP-1 cells were incubated with 50%
of LPDS derived from CAD patients. (a) and (b): npo0.01 vs 0; †po0.01 vs 200; ‡po0.01 vs 400. (c) and (d): npo0.01 vs S0; †po0.01 vs S10; ‡po0.01 vs S30.
Fig. 3. Gene expression in THP-1 cells enriched with serum and LPDS derived from CAD and C. THP-1 cells were incubated without and with 50% serum and 50% LPDS
derived from stable CAD patients and healthy controls (C) for 6 h at 37 1C. (a) mRNA of GRP78/BiP, CHOP, Nrf2, HO-1, and GCLC was analyzed by quantitative real-time PCR.
Normalized gene expression levels are given as the ratio between the mean value for the target gene and that for the β-actin in each sample. (b) Representative Western blot
analysis for the indicated proteins and the average quantiﬁcation obtained by densitometric analysis of all the samples derived from healthy controls and CAD patients.
Data from the Western blot analysis are expressed as the density ratio of target protein (row 1) to control (β-actin, row 2) in arbitrary units. Data represent the mean7SD of
measurements performed in triplicate. npo0.01 vs S50 healthy controls (C).
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endothelial cells [28]. In this study we found that plasma and
PBMC concentrations of oxPAPC were signiﬁcantly higher in CAD
patients compared to healthy C. The reason plasma oxPAPC is
higher in CAD patients than in healthy C may merely reﬂect the
concentration of circulating ox-LDL. Ox-LDL, in fact, has previously
been shown to contain signiﬁcant amounts of oxPAPC [29]. The
fact that in our study oxPAPC were higher in LDL of CAD patients
than in that of healthy C directly conﬁrms that the increase in
plasma oxPAPC in CAD patients may, at least partially, be related to
the levels of circulating ox-LDL. In contrast. the reason PBMCs of
CAD patients have a higher concentration of oxPAPC than healthy
C is currently unclear. However, it is known that there is a
persistent interchange and mobility between oxPAPC in cell
membranes [30–34]. We have hypothesized that there may be
an interchange also between circulating ox-LDL and PBMCs. As a
matter of fact, when the monocytoid THP-1 cells were incubated
with ox-LDL, but not with n-LDL, there was a signiﬁcant exchange
of oxPAPC from ox-LDL to PBMCs, meaning that ox-LDL may be a
source of oxPAPC for circulating cells. More interestingly, we also
found that incubation of THP-1 cells with increasing amounts of
serum derived from CAD patients, but not from healthy C, resulted
in a dose-dependent signiﬁcant increase in cellular oxPAPC. To
eliminate the possible interchange between circulating lipopro-
teins and THP-1, we then incubated the cells with LPDS, i.e., a
Fig. 4. Effects of PGPC on ROS generation and on GSH in THP-1 cells. Increasing amounts of PGPC with or without the addition of DPI (50 mM) were incubated with THP-1
cells, and ROS and GSH were measured respectively after 15 min and 6 h of incubation at 37 1C. Data on ROS and GSH are expressed respectively as mean ﬂuorescence
intensity (MFI) in arbitrary units and as ng/mg cell protein. The values of ROS and GSH represent the mean7SD of experiments performed in triplicate on six different
occasions. npo0.01 vs PGPCþDPI; †po0.01 vs PGPC 0.4 ng/mg PAPC; ‡po0.01 vs PGPC 0.8 ng/mg PAPC; §po0.01 vs PGPC 1.2 ng/mg PAPC.
Fig. 5. Effects of PGPC on GRP78/BiP, CHOP, and Nrf2/ARE gene expression in THP-1 cells. Increasing amounts of PGPC with or without the addition of DPI (50 mM) were
incubated with THP-1 cells and mRNA of (a) GRP78/BiP and CHOP and (c) Nrf2 and GCLC was analyzed by quantitative real-time PCR. Normalized gene expression levels are
given as the ratio between the mean value for the target gene and that for the β-actin in each sample. (b, d) Representative Western blot analysis of the indicated proteins
and the average quantiﬁcation obtained by densitometric analysis of all the samples. Data from Western blot analysis are expressed as the density ratio of target protein
(row 1) to control (β-actin, row 2) in arbitrary units. Data represent the mean7SD of measurements performed in triplicate on six different occasions. npo0.01 vs control;
†po0.01 vs GRP78/BiP and CHOP; ‡po0.01 vs PGPC 0.8 ng/mg PAPC.
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serum deprived of lipoproteins. The fact that the incubation of
THP-1 cells with LPDS almost completely abolished the increase in
cellular oxPAPC suggests that the serum lipoproteins and in
particular ox-LDL may be a major source of oxPAPC for circulating
cells. In THP-1 cells enriched with oxPAPC, the expression of
GRP78/BiP and CHOP was higher in cells incubated with serum
derived from CAD patients compared to that from healthy C. When
THP-1 cells were incubated with LPDS only small, and not
signiﬁcant, variations in GRP78/BiP and CHOP expression were
observed, suggesting that the interchange of oxPAPC between ox-
LDL and PBMC may have a role in inducing UPR and ER-initiated
apoptotic signaling. However, it is well known that ox-LDL con-
tains a plethora of lipid oxidation products that may exert
proapoptotic effects [35]. On the basis of the present results,
therefore, we cannot exclude that, under our experimental condi-
tions, other oxidized lipids interchanged between ox-LDL and
PBMCs and contributed to ER stress observed in CAD. Furthermore
it has to be emphasized that growing evidence suggests that
signaling pathways in the UPR and inﬂammation are intercon-
nected through various mechanisms and in particular through the
activation of nuclear factor κB [36], a master transcription factor
with numerous functions including regulation of the inﬂammatory
response. In this context, we have previously reported that ox-LDL
induced an inﬂammatory response via speciﬁc receptors in both
stable and unstable CAD patients, the phenomenon, however,
being much more evident in the latter than in the former [14–16].
Provided that the slight increase in hs-CRP we found in this study in
stable CAD patients is related to a mechanism other than ER stress,
on the basis of the present results we cannot exclude that inﬂam-
mation may have, at least partially, taken an active part in the
induction of UPR. Further studies are needed to explore in more
detail how ER stress can be affected by the extent of inﬂammatory
response.
Unexpectedly, our results also show that oxPAPC-induced UPR
and ER-initiated apoptotic signaling observed in PBMCs of CAD
patients were not associated with an adequate expression of the
genes correlated to the activity of the Nrf2/ARE system, one of the
most important cellular defense mechanism against excess of ROS
[12,13]. The inadequate response of the Nrf2/ARE system was
observed both in PBMCs of CAD patients and in oxPAPC-enriched
THP-1 cells. Our results are in line with a series of studies in which
the same inadequacy was reported in other chronic pathologies
such as chronic renal failure [37] and chronic obstructive pulmon-
ary disease [38]. Although the precise mechanism of decreased
Nrf2/ARE expression in chronic pathologies remains to be fully
determined, a partial explanation of these results may derive from
a recent paper from our group [19] in which monocytes from
heavy smokers with the highest production of ROS did not
appropriately react in terms of Nrf2/ARE activation. Actually when
in our study we analyzed the dose-dependent effect of PGPC on
ROS generation in THP-1 cells, in agreement with previously
published data [19], we found that PGPC dose-dependently
increased ROS formation and that this effect was dependent on
the activation of NADPH oxidase because it was inhibited by DPI,
a speciﬁc inhibitor of the enzyme. GRP78/BiP and CHOP expression
induced by PGPC in THP-1 cells paralleled the dose-dependent
increase in ROS, and their expression was inhibited by DPI.
In contrast, the behavior of Nrf2/ARE gene expression induced by
PGPC was different depending on its concentration. At low con-
centrations, PGPC evoked a dose-dependent rise in Nrf2 and GCLC,
whereas at higher concentrations, it reduced Nrf2/ARE gene
expression. The repression of Nrf2/ARE gene activation was
reversed at the highest concentrations of PGPC by DPI, suggesting
that the amount of intracellular ROS may be one of the determi-
nants of the inadequate response of Nrf2/ARE genes. So it is likely
that it is an excess of oxidative stress that orchestrates the switch
from the protective UPR and Nrf2/ARE gene expression to ER-
initiated apoptotic signaling.
Conclusions
So, in conclusion, the results of this study show that PBMCs of
stable CAD patients are characterized by the activation of UPR and
of ER-initiated apoptotic signaling without an adequate Nrf2/ARE
response. An excess of systemic oxidative stress with an inter-
change of oxPAPC between ox-LDL and PBMC may markedly
contribute to the condition of ER stress observed in CAD.
References
[1] Mathers, C. D.; Loncar, D. Projection of global mortality and burden of disease
from 2002 to 2030. PLoS Med 3:2011–2030; 2006.
[2] Go, A. S.; Mozaffarian, D.; Roger, V. L.; Benjamin, E. J.; Berry, J. D.; Borden, W.
B.; Bravata, D. M.; Dai, S.; Ford, E. S.; Fox, C. S.; Franco, S.; Fullerton, H. J.;
Gillespie, C.; Hailpern, S. M.; Heit, J. A.; Howard, V. J.; Huffman, M. D.; Kissela,
B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Magid, D.;
Marcus, G. M.; Marelli, A.; Matchar, D. B.; McGuire, D. K.; Mohler, E. R.; Moy, C.
S.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Schreiner, P. J.; Sorlie, P. D.; Stein,
J.; Turan, T. N.; Virani, S. S.; Wong, N. D.; Woo, D.; Turner, M. B. Executive
summary: heart disease and stroke statistics—2013 update: a report from the
American Heart Association. Circulation 127:143–152; 2013.
[3] Tabas, I. The role of endoplasmic reticulum stress in the progression of
atherosclerosis. Circ. Res. 7:839–850; 2010.
[4] Kaufman, R. J. Orchestrating the unfolded protein response in health and
disease. J. Clin. Invest. 110:1389–1398; 2002.
[5] Ron, D.; Walter, P. Signal integration in the endoplasmic reticulum unfolded
protein response. Nat. Rev. Mol. Cell. Biol. 8:519–529; 2007.
[6] Gargalovic, P. S.; Gharavi, N. M.; Clark, M. J.; Pagnon, J.; Yang, W. P.; He, A.;
Truong, A.; Baruch-Oren, T.; Berliner, J. A.; Kirchgessner, T. G.; Lusis, A. J. The
unfolded protein response is an important regulator of inﬂammatory genes in
endothelial cells. Arterioscler. Thromb. Vasc. Biol. 26:2490–2496; 2006.
[7] Kim, I.; Xu, W.; Reed, J. C. Cell death and endoplasmic reticulum stress: disease
relevance and therapeutic opportunities. Nat. Rev. Drug Discovery 7:1013–-
1030; 2008.
[8] Kansanen, E.; Jyrkkanen, H.; Levonen, A. Activation of stress signaling path-
ways by electrophilic oxidized and nitrated lipids. Free Radic. Biol. Med.
52:973–982; 2012.
[9] Bertolotti, A.; Zhang, Y.; Hendershot, L. M.; Harding, H. P.; Ron, D. Dynamic
interaction of BiP and ER stress transducers in the unfolded-protein response.
Nat. Cell Biol. 2:326–332; 2000.
[10] Thorp, E.; Li, G.; Seimon, T.; Kuriakose, G.; Ron, D.; Tabas, I. Reduced apoptosis
and plaque necrosis in advanced atherosclerotic lesions of Apoe/ and
Ldlr/ mice lacking CHOP. Cell Metab. 9:474–481; 2009.
[11] McCullough, K. D.; Martindale, J. L.; Klotz, L. O.; Aw, T. Y.; Holbrook, N. J.
Gadd153 sensitizes cells to endoplasmic reticulum stress by down-regulating
Bcl2 and perturbing the cellular redox state. Mol. Cell. Biol. 21:1249–1259;
2001.
[12] Cullinan, S. B.; Diehl, J. A. PERK-dependent activation of Nrf2 contributes to
redox homeostasis and cell survival following endoplasmic reticulum stress.
J. Biol. Chem. 279:20108–20117; 2004.
[13] Singh, S.; Vrishni, S.; Singh, B. K.; Rahman, I.; Kakkar, P. Nrf2/ARE stress
response mechanism: a control point in oxidative stress mediated dysfunction
and chronic inﬂammatory disease. Free Radic. Res. 44:1267–1288; 2010.
[14] Cominacini, L.; Anselmi, M.; Garbin, U.; Fratta Pasini, A.; Stranieri, C.; Fusaro,
M.; Nava, C.; Agostoni, P.; Keta, D.; Zardini, P.; Sawamura, T.; Lo Cascio, V.
Enhanced plasma levels of oxidized low-density lipoprotein increase circulat-
ing nuclear factor-kappa B activation in patients with unstable angina. J. Am.
Coll. Cardiol. 46:799–806; 2005.
[15] Anselmi, M.; Garbin, U.; Agostoni, P.; Fusaro, M.; Pasini, A. F.; Nava, C.; Keta, D.;
Turri, M.; Zardini, P.; Vassanelli, C.; Lo Cascio, V.; Cominacini, L. Plasma levels
of oxidized-low-density lipoproteins are higher in patients with unstable
angina and correlated with angiographic coronary complex plaque. Athero-
sclerosis 185:114–120; 2006.
[16] Fratta Pasini, A.; Anselmi, M.; Garbin, U.; Franchi, E.; Stranieri, C.; Nava, M. C.;
Boccioletti, V.; Vassanelli, C.; Cominacini, L. Enhanced levels of oxidized low-
density lipoprotein prime monocytes to cytokine overproduction via up-
regulation of CD14 and toll-like receptor 4 in unstable angina. Arterioscler.
Thromb. Vasc. Biol. 27:1991–1997; 2007.
[17] Braunwald, E. Unstable angina: a classiﬁcation. Circulation 80:410–414; 1989.
[18] Evans, K.; Mitcheson, J.; Laker, M. F. Effect of storage at 70 degrees C on lipid,
lipoprotein and apolipoprotein concentrations. Clin. Chim. Acta 258:219–229;
1997.
[19] Garbin, U.; Fratta Pasini, A.; Stranieri, C.; Cominacini, M.; Pasini, A.; Manfro, S.;
Lugoboni, F.; Mozzini, C.; Guidi, G.; Faccini, G.; Cominacini, L. Cigarette
smoking blocks the protective expression of Nrf2/ARE pathway in peripheral
C. Mozzini et al. / Free Radical Biology and Medicine 68 (2014) 178–185184
mononuclear cells of young heavy smokers favouring inﬂammation. PLoS One
4; 2009e8225 4; 2009.
[20] Watson, A. D.; Leitinger, N.; Navab, M.; Faull, K. F.; Hörkkö, S.; Witztum, J. L.;
Palinski, W.; Schwenke, D.; Salomon, R. G.; Sha, W.; Subbanagounder, G.;
Fogelman, A. M.; Berliner, J. A. Structural identiﬁcation by mass spectrometry
of oxidized phospholipids in minimally oxidized low density lipoprotein that
induce monocyte/endothelial interactions and evidence for their presence
in vivo. J. Biol. Chem. 272:13597–13607; 1997.
[21] Cominacini, L.; Fratta Pasini, A.; Garbin, U.; Davoli, A.; Tosetti, M. L.;
Campagnola, M.; Rigoni, A.; Pastorino, A. M.; Lo Cascio, V.; Sawamura, T.
Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in
endothelial cells induces the activation of NF-kappaB through an increased
production of intracellular reactive oxygen species. J. Biol. Chem. 275:12633–-
12638; 2000.
[22] Myoishi, M.; Hao, H.; Minamino, T.; Watanabe, K.; Nishihira, K.; Hatakeyama, K.;
Asada, Y.; Okada, K.; Ishibashi-Ueda, H.; Gabbiani, G.; Bochaton-Piallat, M. L.;
Mochizuki, N.; Kitakaze, M. Increased endoplasmic reticulum stress in athero-
sclerotic plaques associated with acute coronary syndrome. Circulation
116:1226–1233; 2007.
[23] Hansson, G. Inﬂammation, atherosclerosis and coronary artery disease. N. Engl.
J. Med. 352:1685–1695; 2005.
[24] Garbin, U.; Baggio, E.; Stranieri, C.; Pasini, A.; Manfro, S.; Mozzini, C.; Vallerio,
P.; Lipari, G.; Merigo, F.; Guidi, G.; Cominacini, L.; Fratta Pasini, A. Expansion of
necrotic core and shedding of Mertk receptor in human carotid plaques: a role
for oxidized polyunsaturated fatty acids? Cardiovasc. Res. 97:125–133; 2013.
[25] Ridker, P. M.; Cannon, C. P.; Morrow, D.; Rifai, N.; Rose, L. M.; McCabe, C. H.;
Pfeffer, M. A.; Braunwald, E. C-reactive protein levels and outcomes after statin
therapy. N. Engl. J. Med. 352:20–28; 2005.
[26] Cavalca, V.; Veglia, F.; Squellerio, I.; Marenzi, G.; Minardi, F.; De Metrio, M.;
Cighetti, G.; Boccotti, L.; Ravagnani, P.; Tremoli, E. Glutathione, vitamin E and
oxidative stress in coronary artery disease: relevance of age and gender. Eur. J.
Clin. Invest. 39:267–272; 2009.
[27] Elesber, A.; Best, P.; Lennon, R.; Mathew, V.; Rihal, C. S.; Lerman, L. O.; Lerman,
A. Plasma 8-iso-prostaglandin F2α, a marker of oxidative stress, is increased in
patients with acute myocardial infarction. Free Radic. Res. 40:385–391; 2006.
[28] Sanson, M.; Augé, N.; Vindis, C.; Muller, C.; Bando, Y.; Thiers, J. C.; Marachet, M. A.;
Zarkovic, K.; Sawa, Y.; Salvayre, R.; Nègre-Salvayre, A. Oxidized low-density
lipoproteins trigger endoplasmic reticulum stress in vascular cells: prevention by
oxygen-regulated protein 150 expression. Circ. Res. 104:328–336; 2009.
[29] Ishii, H.; Tezuka, T.; Ishikawa, H.; Takada, K.; Oida, K.; Horie, S. Oxidized
phospholipids in oxidized low-density lipoprotein down-regulate thrombo-
modulin transcription in vascular endothelial cells through a decrease in the
binding of RARbeta-RXRalpha heterodimers and Sp1 and Sp3 to their binding
sequences in the TM promoter. Blood 101:4749–4765; 2003.
[30] Stemmer, U.; Dunai, Z.; Koller, D.; Koller, D.; Purtsinger, G.; Zenzmaier, E.;
Deigner, H. P.; Aﬂaki, E.; Kratky, D.; Hermetter, A. Toxicity of oxidized
phospholipids in cultured macrophages. Lipids Health Dis. 11:110; 2012.
[31] Stemmer, U.; Ramprecht, C.; Zenzmaier, E.; Stojčić, B.; Rechberger, G.;
Kollroser, M.; Hermetter, A. Uptake and protein targeting of ﬂuorescent
oxidized phospholipids in cultured RWA 264.7 macrophages. Biochim. Biophys.
Acta 1821:706–718; 2012.
[32] Stemmer, U.; Hermetter, A. Protein modiﬁcation by aldehydophospholipids
and its functional consequences. Biochim. Biophys. Acta 1818:2436–2445;
2012.
[33] Friedman, P.; Horkko, S.; Steinberg, D.; Witztum, J. L.; Dennis, E. A. Correlation
of antiphospholipid antibody recognition with the structure of synthetic
oxidized phospholipids: importance of Schiff base formation and aldol
condensation. J. Biol. Chem. 277:7010–7020; 2002.
[34] Rhode, S.; Grurl, R.; Brameshuber, M.; Hermetter, A.; Schutz, G. J. Plasma
membrane ﬂuidity affects transient immobilization of oxidized phospholipids
in endocytotic sites for subsequent uptake. J. Biol. Chem. 284:2258–2265;
2009.
[35] Parthasarathy, S.; Raghavamenon, A.; Garelnabi, A. M.; Santanam, N. Oxidized
low-density lipoprotein. Methods Mol. Biol. 610:403–417; 2010.
[36] Hotamisligil, G. S. Endoplasmic reticulum stress and the inﬂammatory basis of
metabolic disease. Cell 140:900–917; 2010.
[37] Kim, H.; Vaziri, N. Contribution of impaired Nrf2–Keap1 pathway to oxidative
stress and inﬂammation in chronic renal failure. Am. J. Physiol. Renal Physiol.
298:F662–F671; 2010.
[38] Suzuki, M.; Betsuyaku, T.; Ito, Y.; Nagai, K.; Nasuhara, Y.; Kaga, K.; Kondo, S.;
Nishimura, M. Down-regulated NF-E2 related factor 2 in pulmonary macro-
phages of aged smokers and patients with chronic obstructive pulmonary
disease. Am. J. Respir. Cell Mol. Biol. 39:673–682; 2008.
C. Mozzini et al. / Free Radical Biology and Medicine 68 (2014) 178–185 185
